140 stories
GLP-1 receptor agonists are the most consequential drug class to emerge in obesity and type-2 diabetes since metformin. The category started with exenatide and liraglutide, broke commercial ceilings with semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and is now expanding into orals (orforglipron, oral semaglutide), triple agonists (retatrutide), and amylin combinations (cagrisema, eloralintide).
The signal worth tracking has shifted. Weight loss alone is no longer the headline — secondary indications are. SELECT showed a 20% drop in major adverse cardiovascular events for non-diabetic adults with obesity. A Mass General Brigham analysis in JAMA reported 42–58% lower heart-failure hospitalizations in HFpEF. AAN 2026 added migraine, dementia incidence, and Parkinson's signals to the growing list. The Phase 3 EVOKE Alzheimer's trial, by contrast, missed its endpoint.
Gallup's July 7, 2026 poll release documented the first large-population evidence that GLP-1 uptake is bending the US obesity curve: 11% of US adults now take a GLP-1 for weight loss (up from 3% in 2024 and 8% in 2025), and the US adult obesity rate has drifted from a 2022 peak of 39.9% down to 36.4% in 2026. Awareness climbed from 80% to 91% over the same span. Browse the latest below, or filter by drug at #semaglutide, #tirzepatide, #orforglipron, and #retatrutide.
Stanford researchers found approximately 10% of people may have resistance to GLP-1 drugs, limiting effectiveness for glucose regulation and weight loss. The study examined individual variation in how GLP-1 drugs slow gastric emptying.
The Atlantic examines how GLP-1 pills are reshaping obesity treatment. The shift from weekly injections to daily pills addresses a major compliance barrier, though patients must continue therapy indefinitely.
Eli Lilly formally launched Foundayo (orforglipron) eight days after FDA approval, having pre-stocked $1.5 billion worth of the drug. The oral obesity market now features a direct Lilly vs Novo Nordisk competition.
The FDA is intensifying enforcement against compounding pharmacies selling unapproved GLP-1 products, threatening seizure and injunction. Hims & Hers was specifically named following the February 2026 TrumpRx launch.
Clarivate projects orforglipron and retatrutide as the defining GLP-1 drugs of the next decade. Retatrutide is projected for 2028 launch after seven additional Phase III readouts expected this year.
MetaVia dosed the first patient in a higher-dose Phase 1 study of DA-1726, its GLP-1 and glucagon dual agonist for obesity treatment, marking continued advancement in next-gen weight loss drugs.
A new review highlights GLP-1 RAs achieving a 55% reduction in apnea-hypopnea index and 14.9% mean weight loss in non-diabetic populations, with pleiotropic effects across cardiovascular, renal, and skeletal systems.
A large GWAS study published in Nature identified a missense variant in GLP1R predicting an additional 0.76 kg of weight loss per allele copy. GIPR variation was linked to nausea/vomiting side effects specific to tirzepatide users.
Combining multiple peptides like GHK-Cu, BPC-157, and TB-500 is becoming a growing trend, especially among GLP-1 medication users dealing with skin laxity from rapid weight loss. Goop feature explores risks and benefits with dermatologist input.
Based on analysis of 107,910 patients, the FDA concluded there is no increased suicide risk associated with GLP-1 medications and has requested removal of related warning labels.
The FLOW trial showed semaglutide reduced major kidney events by 24%, and retatrutide demonstrated up to 28.7% weight loss in TRIUMPH-4. The full pipeline including CagriSema, MariTide, and survodutide was presented.
Comprehensive review examining GLP-1 receptor agonists for neurological conditions. A recent NEJM trial showed GLP-1 treatment resulted in less motor disability progression at 12 months.
The FDA published warning letters targeting companies marketing GLP-1 receptor agonists without regulatory approval, addressing CGMP violations and clinical trial protocol failures.
Retatrutide met its primary endpoint of superior A1C reduction and all key secondary endpoints at 40 weeks compared with placebo in type 2 diabetes patients, also demonstrating significant weight loss.
TikTok users on retatrutide report emotional blunting. Neuroscientist Paul Kenny of Mount Sinai says researchers are investigating whether GLP-1 drugs act as general reward dampeners affecting the brain's mesolimbic system.
Wall Street bets GLP-1 drugs will transform food. Packaged-food giants are down 50%+ from peaks. Goldman projects these drugs could add over 1% to GDP if adoption reaches 60 million Americans by 2028.
The FDA announced steps to restrict compounded GLP-1 products, specifically naming Hims & Hers. Novo Nordisk has also sued Hims & Hers over compounded semaglutide.
India's drug regulators are intensifying GLP-1 oversight ahead of semaglutide's patent expiry. The Drug Controller General audited 49 entities and issued notices to violators.